Bildkälla: Stockfoto

Medivir Q3 2022: fostrox’s dose escalation is nearing completion - Redeye

Redeye comments on Medivir's third quarter report. There have been some positive developments in fostrox's ongoing clinical trial in liver cancer, and the full results from the LEAP-02 trial, which studied lenvatinib + pembrolizumab, have now been published.

Redeye comments on Medivir's third quarter report. There have been some positive developments in fostrox's ongoing clinical trial in liver cancer, and the full results from the LEAP-02 trial, which studied lenvatinib + pembrolizumab, have now been published.
Börsvärldens nyhetsbrev
ANNONSER